Live Attenuated Vaccines Market Report 2026

Live Attenuated Vaccines Market Overview

• Live Attenuated Vaccines market size has reached to $25.95 billion in 2025 • Expected to grow to $41.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: The Increasing Prevalence Of Infectious Diseases Is Fueling The Growth Of The Market Due To Rising Global Incidence And Demand For Effective Long-Term Immunization • Market Trend: Advancements In Single-Dose Live Attenuated Vaccines For Enhanced Immunization • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Live Attenuated Vaccines Market?

Live attenuated vaccines are biological formulations that use a weakened version of a virus or bacterium, engineered in the lab to prevent it from causing illness in healthy individuals. By closely simulating a natural infection, these vaccines trigger a robust and long-lasting immune response, often requiring only one or two doses for effective protection against infectious diseases. The main types of live attenuated vaccines include monovalent and multivalent. Monovalent refers to a substance, such as a vaccine or ion, that is effective against or involves only one specific antigen, strain, or type. It is administered through various routes of administration, such as intramuscular, subcutaneous, oral attenuated, and intranasal attenuated, for several indications, including influenza, measles, mumps, and rubella (MMR), polio, chickenpox, shingles, rotavirus, and others. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end-users, including hospitals, clinics, diagnostic centers, research institutes, and others.

What Is The Live Attenuated Vaccines Market Growth Forecast?

The live attenuated vaccines market size is expected to see strong growth in the next few years. It will grow to $41.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to booster vaccination demand, emerging infectious disease risks, cold chain infrastructure expansion, global health funding, next-generation vaccine platforms. Major trends in the forecast period include expansion of national immunization programs, growing demand for pediatric vaccination, advances in vaccine stability and storage, increased focus on pandemic preparedness, multivalent vaccine development.

Global Live Attenuated Vaccines Market Segmentation

1) By Vaccine Type: Monovalent, Multivalent 2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated 3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users Subsegments: 1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines 2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

What Is The Driver Of The Live Attenuated Vaccines Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the live attenuated vaccines market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from one person, animal, or environment to another. Rising global travel accelerates the spread of infectious diseases by allowing pathogens to cross borders faster than containment efforts. Live attenuated vaccines help prevent infectious diseases by stimulating a strong immune response with weakened pathogens, ensuring long-term immunity and reducing disease spread. For instance, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2023, an estimated 10.8 million people fell ill with TB worldwide, including 6.0 million men, 3.6 million women, and 1.3 million children. Therefore, the increasing prevalence of infectious diseases is driving the growth of the live attenuated vaccines industry.

Key Players In The Global Live Attenuated Vaccines Market

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Global Live Attenuated Vaccines Market Trends and Insights

Major companies operating in the live attenuated vaccines market are focusing on developing advanced products such as single-dose vaccines to enhance immunization efficiency and improve patient compliance. Single-dose vaccines provide lasting immunity with a single shot, eliminating the need for multiple doses. This simplifies vaccination for patients and healthcare providers, enhancing convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that manufactures vaccines for infectious diseases, announced the launch of IXCHIQ, which received approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. It is the world’s first live-attenuated chikungunya vaccine indicated for adults aged 18 and older. This approval is significant because IXCHIQ is the world's first licensed vaccine for chikungunya, addressing an unmet medical need for protection against this mosquito-borne viral disease, which can cause severe fever, joint and muscle pain, and other symptoms

What Are Latest Mergers And Acquisitions In The Live Attenuated Vaccines Market?

In May 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired a travel health business from Emergent BioSolutions Inc. for approximately $380 million. With this acquisition, Bavarian Nordic aims to expand its vaccine portfolio, including VIVOTIF for typhoid fever, VAXCHORA for cholera, and the chikungunya vaccine candidate CHIKV VLP, along with its manufacturing and development facilities in Switzerland and California. Emergent BioSolutions Inc. is a US-based biopharmaceutical company that manufactures live attenuated vaccines.

Regional Insights

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Live Attenuated Vaccines Market?

The live attenuated vaccine market consists of sales of viral live attenuated vaccines, bacterial live attenuated vaccines, and intranasal live attenuated vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Live Attenuated Vaccines Market Report 2026?

The live attenuated vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.